Swiss Rockets

Founded in 2018 and headquartered in Basel, Switzerland, Swiss Rockets AG is an innovative biotechnology group that functions as an incubator and accelerator for niche-leading biotech startups. The company develops and supports portfolio enterprises across fields including oncology, radioligand therapy, neurology, infectious diseases, and gene sequencing. By providing specialized scientific expertise, operational infrastructure, and global networking, Swiss Rockets aims to drive research, development, and commercialization. Its approach integrates advanced technologies and drug discovery capabilities to navigate the path from late-stage pre-clinical development through to Phase III clinical trials.

The group is dedicated to transforming treatment standards for cancer, infectious diseases, and autoimmune disorders to improve patient outcomes worldwide. Through its subsidiaries, such as Rocketvax for vaccines and Torpedo Pharmaceuticals for next-generation radioligand therapies, the organization addresses urgent medical needs with innovative drug development. Swiss Rockets supports its portfolio companies with regulatory, financial, and technical resources, ensuring they are well-positioned to bring groundbreaking medical solutions to market. By fostering a community of investors and maintaining strategic partnerships, the group works to shape a more equitable and effective future for global healthcare.